Information on this page is updated every few minutes. You do not have to refresh your browser. It will refresh itself every couple of minutes.    NOTE: THIS WEB PAGE IS NOT UPDATED DURING MARKET HOURS.


CELLCEUTIX CORP   (CTIX)    




  Last Open: 3.0000       Last Price: 2.9600     ( -1.33 %)     Total Volume: 630800 shares      Float: 65.59M shares
  High of the Day: 3.0000       Low of the Day: 2.7700      Last Price is in the top   82.61% of the day's trading range.
  Trades below current price: 90%       Volume traded below current price: 78%
  Trades during last 15 minutes: 4.22%     Trades during last hour: 13.25%    
  Volume traded during last 15 minutes: 3.25%     Volume traded During Last Hour: 6.85%    

  Short Volume traded last trading session: 0 shares       (0 % of total volume traded )
  Short Volume traded two trading sessions ago: 759562 shares       ( 46.50 % of total volume traded )


  Current Promotion Campaign Start Date:   09/09/13
  Number of Known Previous Campaigns:   0


  Promotional Newsletters Sent       Last Hour: 0     Last Four Hours: 0     Last Eight Hours: 0     Last Sixteen Hours: 0

  Promoters Sending Newsletters During Last Hour: NONE
  One to Four Hours: NONE
  Four to Eight Hours: NONE
  Eight to Sixteen Hours: NONE


  Press Releases / News       Last Hour: 0     Last Four Hours: 0     Last Eight Hours: 0     Last Sixteen Hours: 0

CELLCEUTIX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits    (Wed, 24 Sep 2014 19:48:22 GMT)
Cellceutix Provides Update to Shareholders    (Wed, 24 Sep 2014 16:28:57 GMT)
CELLCEUTIX CORP Financials    (Sat, 20 Sep 2014 17:04:09 GMT)
Cellceutix to President Obama: We Have the Tools and Will Rise Up to the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a Serious Threat to Public Health    (Fri, 19 Sep 2014 11:15:00 GMT)
CELLCEUTIX CORP Files SEC form 10-K, Annual Report    (Mon, 15 Sep 2014 17:50:04 GMT)
Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis    (Tue, 09 Sep 2014 19:00:00 GMT)
Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference    (Fri, 05 Sep 2014 15:15:46 GMT)
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting    (Tue, 02 Sep 2014 11:00:00 GMT)
CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and    (Tue, 02 Sep 2014 10:29:26 GMT)
Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)    (Tue, 19 Aug 2014 12:30:00 GMT)
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis    (Mon, 11 Aug 2014 11:00:00 GMT)
Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial    (Thu, 07 Aug 2014 13:02:28 GMT)
Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial for Acute Bacterial Skin and Skin Structure Infections Expected This Month    (Mon, 04 Aug 2014 11:00:00 GMT)
Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers    (Mon, 14 Jul 2014 11:00:00 GMT)
Cellceutix Brilacidin ABSSSI Trial Gets Positive Review by Data Safety Monitoring Board; Best Possible Outcome, No Treatment-Related Serious Adverse Events (SAEs)    (Mon, 07 Jul 2014 11:00:00 GMT)
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant    (Mon, 23 Jun 2014 11:00:00 GMT)
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort    (Mon, 16 Jun 2014 11:00:00 GMT)
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol    (Mon, 02 Jun 2014 11:00:00 GMT)
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities    (Tue, 27 May 2014 11:00:00 GMT)
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market    (Mon, 19 May 2014 11:00:00 GMT)



  Twitter Activity     Last Two Hours: 0    Last Four Hours: 0    Last Eight Hours: 2

  Tweets in the last two hours from: